Maxim 1
2 Parklands Way Holytown
Motherwell ML1 4WR
United Kingdom
44 14 1433 7557
https://tcbiopharm.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 41
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Bryan L. Kobel | CEO & Director | 544,56k | N/D | 1979 |
Mr. Martin E. Thorp | CFO & Director | 410,52k | N/D | 1952 |
Mr. Christopher Camarra | Executive Vice President of Communications | N/D | N/D | N/D |
Dr. Lauren Bor Ph.D. | Head of Commercial Development Division | N/D | N/D | N/D |
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
L'ISS Governance QualityScore di TC Biopharm (Holdings) Plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.